1. Medtech Insight
  2. >>Device Area
  3. >>Orthopedics

Market Intel: Innovation, Surgical Techniques Drive Arthroscopy, Sports Medicine Products Market

 
• By Marion Webb

The global market for arthroscopy products and sports medicine devices is expected to reach $9bn by 2023, a CAGR of 4.2%, driven by technological advancements, improved surgical techniques and a growing number of surgeons performing minimally invasive surgeries. With hip fixation devices expected to see double-digit growth by 2023, we'll take a closer look at recent technological innovations driving this sector, the key players, and also offer viewpoints from four orthopedic surgeons on what is driving their decision to adopt technologies. We'll also highlight the latest arthroscopes on the market, which is the fastest-growing segment in the global arthroscopy products market.

Sports hip injury koncept - Illustration

Global sales for arthroscopy products and sports medicine devices are expected to reach $9bn by 2023, representing a CAGR of 4.2% from 2018. Over the last few years, the value of the sports medicine market has risen to be nearly equal to the arthroscopy market. Within the combined market, arthroscopy products accounted for 51.9% of sales and sports medicine implants account for the remaining 48.1%. By 2023, the smaller sports medicine sector is expected to surpass arthroscopy product sales. (Also see "Device Week, 10 May 2019 – Global Arthroscopy Products Market; Biotronik Starts First ICD Study Looking At Sex-Specific Outcomes " - Medtech Insight, 10 May, 2019.)

According to a new report by Informa's Meddevicetracker, "Arthroscopy Products and Sports Medicine Implants," worldwide sales of arthroscopy products are expected to climb from $3.8bn in 2018 to $4.4bn...

More from Orthopedics

More from Device Area

Handheld Diagnostics: A Resurging Category That is Here to Stay

 
• By Barnaby Pickering

Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By Elizabeth Orr

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel